Authors
Latest:
PARP inhibitors: Treating mCRPC from a genetic basisTreatments provide a targeted therapeutic strategy for metastatic castration-resistant prostate cancer.
Latest:
The safety and oncologic benefits of transperineal vs transrectal MRI-guided prostate biopsy"These studies, taken together, offer important insight into the direction we should be heading in prostate cancer diagnosis: toward a targeted-only TP biopsy," write Tarik Benidir, MD, and Zeyad Schwen, MD.
Latest:
UTI vaccine shows efficacy, safety in men and women"Overall, this vaccine is safe in the long term and our participants reported having fewer UTIs that were less severe," says Bob Yang, MBBS, FRCS.
Latest:
Race-based adjustment of eGFR: Current opinions and impact on urologic oncology“As other factors such as access to care, socioeconomic conditions, patient preference, and other unknown confounders might have played a role in the observed disparity, it is still unclear whether overestimating the postoperative eGFR of Black patients contributes to the lower use of nephron-sparing approaches in this population,” the authors write.
Latest:
Update on advanced imaging in prostate cancerAdvances allow for more accurate detection of metastatic disease.
Latest:
UroView: Gallium 68 PSMA–Targeted PET Imaging in Prostate Cancer: Staging and OutcomesThis article features insights from Phillip Kuo, MD, PhD, and Andre Abreu, MD, on gallium 68 PSMA-targeted PET imaging in prostate cancer.
Latest:
Optimizing Care Collaboration in Advanced Prostate CancerExplore strategies for seamless coordination between urologists and medical oncologists to ensure uninterrupted, patient-focused care in prostate cancer treatment.
Latest:
Medical software should be chosen based on your practice’s life cycle stageAt each stage, health care providers have different priorities and goals, and the choice of medical software solutions should be made accordingly.
Latest:
The current state of adjuvant radiotherapy post prostatectomy: 3 take-home messages"If your practice does not closely monitor patients and send them for early salvage radiotherapy when their PSA is 0.1 or 0.2 ng/mL, it is likely that adjuvant radiotherapy is superior," Daniel E. Spratt, MD, writes.
Latest:
Presentation, diagnosis, and management of a rare case of urachal adenocarcinoma"Urachal carcinoma is a rare and aggressive malignancy. The low incidence of the disease results in limited large-scale clinical trials that could provide standardized guidelines for its diagnosis and management," write Christopher Pieczonka, MD, and Peter Fioramonti, BS.
Latest:
Subgroup data sustain enzalutamide PFS benefit in nmCRPCNo new safety signals were reported with the androgen receptor pathway inhibitor.
Latest:
Continued Advances and Unmet Needs in PSMA-Based Imaging for Prostate CancerExperts Naveen Kella, MD, and Dr. Shadi Esfahani, MD, MPH, consider the continued impact of PSMA PET imaging on prostate cancer management and emerging modalities that could revolutionize patient care.
Latest:
Minimizing incontinence after radical prostatectomy: Lessons learned"I've worked in 3 different countries, I've seen dozens of people doing robotic radical prostatectomy...so my current practice is kind of a “best of” what I have seen and learned," says Ricardo Soares, MD.
Latest:
Neoadjuvant combo boosts MRD negativity rates in high-risk prostate cancerAdding apalutamide to the hormone therapy degarelix in the neoadjuvant setting increased the likelihood of achieving minimal residual disease negativity in patients with high-risk prostate cancer after radical prostatectomy.
Latest:
Physician Commentary: Do EHR upgrades really enhance patient care?"Clinicians, now more than ever, have many data entry duties. The clinical encounter’s efficiency is dictated by the ease of the EHR," write Jesse D. Bracamonte, DO, FAAFP, and Michael Underhill, DO.
Latest:
Case review: An incidentally discovered renal massAn expert panel discusses the case of a 65-year-old Caucasian male who is noted to have an incidental 3-cm right renal mass, enhancing on a contrasted CT scan as part of a routine follow-up for his metastatic castration-resistant prostate cancer, diagnosed in 2017 and currently undergoing therapy.
Latest:
Expert explains how to fully optimize EHRsRecent advances in technology make it possible to access and harness the vast amounts of clinical data EHRs have produced.
Latest:
Exploratory analysis identifies blood-based biomarkers that may predict treatment outcomes in urothelial carcinomaThe exploratory analysis may have showcased the benefit of testing for tertiary lymphoid structures.
Latest:
Front-line maintenance with avelumab found efficacious for locally advanced, metastatic mUCThe real-world data were presented at the 2023 American Society of Clinical Oncology Genitourinary Cancers Symposium.
Latest:
Expert highlights the latest radiotherapy developments in prostate cancer“As the ability to target improved, what we really clearly saw was the idea that perhaps a treatment course could be shortened significantly, and that the term hypofractionation became commonly applied to men with prostate cancer,” said Walter J. Curran Jr, MD, FACR, FASCO.
Latest:
Physician Burnout: Assessing and addressing its impact on your family“A physician struggling under an unbearable weight of emotions, or going to work feeling like they are enduring emotional trauma can have trickle down emotional effects on family members,” writes physician and US Navy veteran Caitlin Delaney, MD.
Latest:
Rucaparib improves rPFS over Physician's Choice for BRCA+ mCRPCTreatment with rucaparib reduced risk of imaging-based progression or death by half in men with BRCA-altered metastatic castration-resistant prostate cancer.
Latest:
Malpractice Consult: Affidavits of merit and why they matterMost states require affidavits for malpractice cases to proceed.
Latest:
Key Takeaways on Evolving Bladder Cancer Treatment LandscapeThe expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.
Latest:
EP. 4B: The Effect of Leuprolide Formulations on Organizational Management Practices in Metastatic Prostate CancerIn this companion article, Brenda Heath, RN, discusses key challenges related to the use of leuprolide acetate and leuprolide mesylate from an organizational management perspective.
Latest:
Quiz: Testicular trauma in 21-year-oldA 21-year-old male presented to the emergency department for evaluation of testicular pain and swelling 5 days after being struck in the groin.
Latest:
Expert emphasizes significance of physician self-careIf you’re a doctor, your job is to take care of others. But too often, that comes at the expense of taking care of yourself.
Latest:
Future Horizons in PSMA-Targeted Imaging and the Management of Prostate CancerExperts close their discussion by highlighting the future landscape of PSMA-targeted imaging in the management of prostate cancer.
Latest:
Key Takeaways on Evolving Bladder Cancer Treatment LandscapeThe expert panel concludes its discussion by providing key takeaways on the evolving bladder cancer treatment landscape following ESMO 2023.
Latest:
Follow-Up After Negative Bone/CT in Prostate Cancer With Molecular RecurrenceDr Raoul Concepcion leads a multidisciplinary expert panel in a discussion about the challenges of long-term follow-up of prostate cancer in patients with negative bone/CT but positive molecular indicators of recurrence.
